Table 2.
COVID cohort baseline characteristics according to the change of fasting glucose category during follow-up of
| Group A | Group B | Group C | p | Missing | |
|---|---|---|---|---|---|
| NFG to NFG | NFG to IFG | NFG to DFG | |||
| IFG to IFG/NFG | IFG to DFG | ||||
| DFG to IFG/NFG | DFG to DFG | ||||
| N | 185 | 66 | 14 | ||
| Age, years | 61 (52–70) | 63 (51–75) | 55 (50.7–57.5) | 0.11 | 0 |
| Sex, male [N (%)] | 123 (66.5) | 42 (63.6) | 14 (100) | 0.026 | 0 |
| BMI | 27.7 (25–31.1) | 28.2 (25.1–31.5) | 29.1 (27.2–31.4) | 0.51 | 2 |
| Ethnicity [N (%)] | |||||
| Caucasian | 155 (83.8) | 53 (80.3) | 92.9) | 0.27 | 0 |
| Hispanic | 19 (10.3) | 12 (18.2) | 0 | ||
| Asian | 4 (2.2) | 0 | 0 | ||
| African | 7 (3.8) | 1 (1.5) | 1 (7.1) | ||
| Comorbidities [N (%)] | |||||
| Hypertension | 76 (41.1) | 29 (43.9) | 4 (28.6) | 0.57 | 0 |
| Coronary Artery Diseases | 13 (7) | 7 (10.6) | 2 (14.3) | 0.47 | |
| COPD | 5 (2.7) | 4 (6.1) | 0 | 0.33 | |
| Chronic Kidney Disease | 11 (5.9) | 8 (12.1) | 1 (7.1) | 0.26 | |
| Cancer | 11 (5.9) | 4 (6.1) | 3 (21.4) | 0.082 | |
| Neurodegenerative disease | 3 (1.6) | 1 (1.5) | 1 (7.1) | 0.33 | |
| Preadmission treatment [N (%)] | |||||
| ASA | 22 (11.9) | 10 (15.4) | 4 (28.6) | 0.19 | 1 |
| Statin | 21 (11.4) | 12 (18.2) | 3 (21.4) | 0.26 | |
| ACE inhibitors | 26 (14.1) | 10 (15.4) | 3 (21.4) | 0.74 | |
| Angiotensin II Receptor Blockers | 26 (14.1) | 6 (9.2) | 1 (7.1) | 0.49 | |
| ACEI and/or ARB | 46 (24.9) | 13 (20) | 4 (28.6) | 0.67 | |
| Calcium channel blockers | 24 (13) | 9 (13.8) | 1 (7.1) | 0.79 | |
| Beta blockers | 34 (18.4) | 14 (21.5) | 3 (21.4) | 0.84 | |
| Admission to the hospital | |||||
| Median time from symptoms to admission, days | 7 (5–10) | 8 (5–11) | 10 (4.5–10) | 0.94 | 0 |
| Symptoms at onset [N (%)] | |||||
| Fever | 170 (94.4) | 61 (92.4) | 13 (92.9) | 0.83 | 5 |
| Dyspnea | 128 (71.1) | 55 (83.3) | 11 (78.6) | 0.14 | |
| Cough | 125 (69.4) | 49 (74.2) | 9 (64.3) | 0.88 | |
| Fatigue/malaise | 117 (65) | 46 (69.7) | 8 (57.1) | 0.62 | |
| Hypo/dysgeusia | 94 (52.8) | 38 (58.2) | 8 (57.1) | 0.72 | |
| Hypo/anosmia | 80 (44.4) | 37 (56.1) | 7 (50) | 0.27 | |
| Myalgia/arthralgia | 66 (36.7) | 25 (37.9) | 3 (21.4) | 0.49 | |
| Headache | 52 (28.9) | 17 (25.8) | 4 (28.6) | 0.89 | |
| Chest pain | 44 (24.4) | 16 (24.2) | 3 (21.4) | 0.97 | |
| Diarrhea | 67(37.2) | 23 (34.8) | 6 (35.7) | 0.94 | |
| Sore throat | 34 (18.9) | 8 (12.1) | 2 (14.3) | 0.44 | |
| Vomiting/nausea | 39 (21.7) | 13 (19.7) | 3 (21.4) | 0.94 | |
| Conjunctivitis | 33 (18.3) | 11 (16.7) | 4 (28.6) | 0.58 | |
| Abdominal pain | 21 (11.7) | 7 (10.6) | 4 (28.6) | 0.16 | |
| Skin rash | 8 (4.7) | 6 (9.7) | 0 | 0.24 | |